TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $550,954 | -58.6% | 61,628 | -28.9% | 0.00% | 0.0% |
| Q2 2023 | $1,331,358 | +10.3% | 86,677 | +61.5% | 0.00% | 0.0% |
| Q1 2023 | $1,206,858 | +26.7% | 53,662 | +18.4% | 0.00% | 0.0% |
| Q4 2022 | $952,890 | -17.3% | 45,311 | -3.1% | 0.00% | 0.0% |
| Q3 2022 | $1,152,000 | +12.7% | 46,755 | +10.8% | 0.00% | 0.0% |
| Q2 2022 | $1,022,000 | -12.1% | 42,181 | -6.6% | 0.00% | 0.0% |
| Q1 2022 | $1,163,000 | -18.8% | 45,154 | -2.1% | 0.00% | 0.0% |
| Q4 2021 | $1,433,000 | +47.7% | 46,124 | +15.4% | 0.00% | 0.0% |
| Q3 2021 | $970,000 | +101.2% | 39,952 | +20.8% | 0.00% | – |
| Q2 2021 | $482,000 | -45.8% | 33,075 | -7.1% | 0.00% | – |
| Q1 2021 | $889,000 | -46.4% | 35,593 | -41.6% | 0.00% | -100.0% |
| Q4 2020 | $1,660,000 | – | 60,909 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |